Boehringer Ingelheim and Novartis have entered into a new strategic collaboration aimed at accelerating the development of ANGPTL3 combination therapy for the treatment of dyslipidemia. Pursuant to this agreement, Novartis has secured an option to obtain exclusive rights outside China for two molecules in the early stages of research and development from Boehringer Ingelheim. Additionally, Novartis has acquired rights to an siRNA candidate molecule, currently in the IND-enabling research phase, intended for the treatment of severe hypertriglyceridemia and mixed dyslipidemia. In exchange, Boehringer Ingelheim will receive an upfront payment of $160 million, with the potential for up to $5.2 billion in milestone payments, and may be eligible for tiered royalties on future commercial sales. Furthermore, Novartis has expressed a preliminary interest in participating in Boehringer Ingelheim's next round of equity financing.